Latest research on Revlimid

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.

Latest findings

She was treated with Revlimid, Velcade, and Dexamethasone beginning in February 2013. [source, 2016]
He was also treated with Velcade, Dexamethasone, and Revlimid before undergoing autologous stem cell transplant in February 2014. [source, 2016]
In our patient, her donor-derived multiple myeloma was treated with Velcade, Revlimid, and Dexamethasone followed by autologous stem cell transplantation. [source, 2016]
There are ∼86,000 new cases of MM occurring worldwide each year, with MM accounting for an estimated 11,090 deaths in the US in 2014 and an estimated 10,390 deaths in Europe in 2012.4 The introduction of the novel agents, including proteasome inhibitors (PIs) (bortezomib – Velcade and carfilzomib – Kyprolis) and immunomodulatory drugs (Thalidomide – Thalomid, lenalidomide – Revlimid, and pomalidomide – Pomalyst), was an important advance in the therapy of MM. [source, 2016]
In the recently reported randomized Phase III Frontline Investigation of Revlimid + Dexamethasone Versus Standard Thalidomide (FIRST) trial in elderly patients with previously untreated MM not eligible for transplantation, a continuous regimen of Rd emerged as the winner with median progression free survival of 25.5 months when compared with 20.7 months for a fixed course (18 cycles) of Rd (Rd18) and 21.2 months for melphalan, Prednisone, and Thalidomide (MPT). [source, 2015]
Lenalidomide is approved for marketing in the United States only under a FDA-approved restricted distribution program called Revlimid risk evaluation and mitigation strategy (REMS). [source, 2015]
Of note, among novel therapeutic agents used in MM clinical management, IMiDs [thalidomide, lenalidomide (CC-5013) and pomalidomide (CC4047)], have the ability to modulate humoral as well as cellular components of the innate and adaptive immune responses, including NK cell activity against cancer cells [5, 19-22]. [source, 2015]
Lenalidomide (trade name: Revlimid), one of the novel drug agents used to treat MM, is the second generation of oral immunomodulatory drugs developed by Celgene Corporation. [source, 2015]
Since CLARITHROMYCIN is a potent CYP3A4 inhibitor [23, 24], we investigated if this may be a potential mechanism for its activity in MM as part of BiRd [Biaxin, lenalidomide (Revlimid), dexamethasone] regimen. [source, 2015]
Ongoing clinical trials investigate other novel agents – retinoids like Tazarotene, antiangiogenic drugs – lenalidomide (Revlimid) [33], selective immunosuppressive agent for T-cells–Forodesine (BCX-1777) [34], synthetic oligonucleotides and toll-like receptor antagonists [35]. [source, 2015]